Biomarker ID | 828 |
PMID | 22146597 |
Year | 2011 |
Biomarker | TARDBP; TLN1; ;PARK7; LEDGF/PSIP1; CALD1; p73; PTEN; PXN; PEX10; KLK3; DBN1; NFAT1; B Tubulin; SOS1; HSF4; TOP1; HSPA1A/B; |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Differentially Expressed |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include (PTEN): Immune system, Disease, T cell receptor regulation of apoptosis, Adaptive immune system, TGF-beta regulation of extracellular matrix |
Experiment | prostate cancer Vs benign prostatic hyperplasia |
Type of Biomarker | Diagnostic |
Cohort | Prostate cancer patient serum samples (n=41) and BPH patient samples without the diagnosis of cancer (n=39) were obtained |
Senstivity | NA |
Specificity | NA |
AUC | 0.927; 0.911; 0.886; 0.789; 0.77; 0.76; 0.675; 0.667; 0.667; 0.606; 0.6; 0.592; 0.591; 0.583; 0.581; 0.567; 0.567; |
Accuracy | NA |
Level Of Significance | p< 0.05 |
Method Used | BCA Protein Assay |
Clinical | No |
Remarks | AUC mentioned for each gene individually |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | TARDBP, TLN1, PARK7, PSIP1, CALD1, p73, PTEN, PXN, PEX10, KLK3, DBN1, NFAT1, B Tubulin, SOS1, HSF4, TOP1, HSPA1A/B |